HUTCHMED
Manufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Kong Center 2 Queen's Rd Central Fl 48 C...Phone Number
+852 21281188Website
www.hutch-med.comRevenue
$548.5 MillionStock Symbol
0013Industry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About HUTCHMED
HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company operates an integrated research and development platform, advancing innovative drug candidates from early discovery through clinical development and global commercialization. It also maintains manufacturing capabilities and a commercial network that supports the distribution of its oncology products as well as selected prescription and consumer healthcare products, with a focus on addressing unmet medical needs through science-driven innovation and strategic collaborations.Explore more
HUTCHMED Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HUTCHMED your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if HUTCHMED had a recent Job posting/layoffs
Check if HUTCHMED has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if HUTCHMED is spiking on competitors!
Earning: See what the market has to say on HUTCHMED recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at HUTCHMED
Funding: Get notified immidiatlly once HUTCHMED has new funding data
Product Launch: Get notified when HUTCHMED launches new products
HUTCHMED, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
HUTCHMED is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HUTCHMED is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HUTCHMED.
HUTCHMED financials insights
Gather financial insights about HUTCHMED, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$100M
Share Placement
$100M
2021
Share Placement
$100M
HUTCHMED Tech Stack
A closer look at the technologies used by HUTCHMED
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
Hiring Plans
HUTCHMED has more open roles in Legal than it has had at any time in the past 12 months.
Hiring Plans
Earnings
reported R&D expenses of $148 million for 2025. Expenses were lower versus 2024 as many late stage trials are in the completion stage, with multiple NDAs now awaiting approvals.
Earnings, Research & Development, Pharmaceuticals, Finance
Project
Business Development, Pharmaceuticals
HUTCHMED News & Media
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in ChinaHUTCHMED to Announce 2026 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HUTCHMED
Sign Up For FreeTo access detailed company insights
HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company operates an integrated research and development platform, advancing innovative drug candidates from early d... Read More
